CF
IMVT icon

Cantor Fitzgerald’s Immunovant IMVT Stock Holding History

Cantor Fitzgerald’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,335
Closed -$560K – 289
2024
Q1 		$560K Buy
+17,335
New +$632K 0.13% 85
2022
Q4 		– Sell
-94,400
Closed -$527K – 742
2022
Q3 		$527K Buy
+94,400
New +$461K 0.01% 497

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Cantor Fitzgerald's IMVT Position: Q2 2024 in Review

Cantor Fitzgerald sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 17,335 shares — an estimated $560K sold.

Cantor Fitzgerald first reported a position in IMVT in Q3 2022 and held it in 2 quarters. The position peaked at $560K in Q1 2024. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

  • Cantor Fitzgerald reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 17,335 Immunovant shares in Q2 2024, an estimated $560K.
  • Cantor Fitzgerald first reported a position in Immunovant in Q3 2022 and held it in 2 quarters.
  • Cantor Fitzgerald's Immunovant position peaked at $560K in Q1 2024.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Cantor Fitzgerald's 13F filing for Q2 2024, filed 14 Aug 2024.